AZ takes aim at BMS’ lead in neoadjuvant NSCLC Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small Share X AZ takes aim at BMS’ lead in neoadjuvant NSCLC https://pharmaphorum.com/news/az-takes-aim-at-bms-lead-in-neoadjuvant-nsclc/
Blueprint cashes in on the past to build its future Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some Share X Blueprint cashes in on the past to build its future https://pharmaphorum.com/news/blueprint-cashes-in-on-the-past-to-build-its-future/
Liver injuries prompt clinical hold on Sanofi BTK drug One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after Share X Liver injuries prompt clinical hold on Sanofi BTK drug https://pharmaphorum.com/news/liver-injuries-prompt-clinical-hold-on-sanofi-btk-drug/
Pfizer claims new $3.2bn COVID jab deal with US government Pfizer and BioNTech have signed a new $3.2 billion supply contract with the US government for COVID-19 vaccines, Share X Pfizer claims new $3.2bn COVID jab deal with US government https://pharmaphorum.com/news/pfizer-claims-new-3-2bn-covid-jab-deal-with-us-government/
Merck launches accelerator programme for AI startups Merck & Co is looking for startup companies applying artificial intelligence, machine-learning and other digital approaches to drug Share X Merck launches accelerator programme for AI startups https://pharmaphorum.com/news/merck-launches-accelerator-programme-for-ai-startups/
FDA rejection of Spero’s tebipenem ‘raises resistance threat’ The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract Share X FDA rejection of Spero’s tebipenem ‘raises resistance threat’ https://pharmaphorum.com/news/fda-rejection-of-speros-tebipenem-raises-resistance-threat/
Pfizer seeks to overturn three RSV vaccine patents held by GSK Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are Share X Pfizer seeks to overturn three RSV vaccine patents held by GSK https://pharmaphorum.com/news/pfizer-seeks-to-overturn-three-rsv-vaccine-patents-held-by-gsk/
Bayer launches digital AI platform for radiology specialists Bayer has stepped up the digital capabilities of its radiology business with the launch of artificial intelligence-based apps Share X Bayer launches digital AI platform for radiology specialists https://pharmaphorum.com/news/bayer-launches-digital-ai-platform-for-radiology-specialists/
Pfizer and Roivant launch autoimmune specialist Priovant The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to Share X Pfizer and Roivant launch autoimmune specialist Priovant https://pharmaphorum.com/news/pfizer-and-roivant-launch-autoimmune-specialist-priovant/
US panel backs Omicron-targeting vaccines for booster campaigns Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according Share X US panel backs Omicron-targeting vaccines for booster campaigns https://pharmaphorum.com/news/us-panel-backs-omicron-targeting-vaccines-for-booster-campaigns/
NHS App could offer video consultations by 2024 The NHS App will be updated over the next couple of years to include a series of new Share X NHS App could offer video consultations by 2024 https://pharmaphorum.com/news/nhs-app-could-offer-video-consultations-by-2024/
Novartis will shed 7% of workforce in restructuring, say reports A Swiss newspaper has said Novartis’ previously announced restructuring programme could lead to 8,000 axed jobs, including up Share X Novartis will shed 7% of workforce in restructuring, say reports https://pharmaphorum.com/news/novartis-will-shed-7-of-workforce-in-restructuring-say-reports/
Gilead tries again with twice-yearly HIV drug lenacapavir Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to Share X Gilead tries again with twice-yearly HIV drug lenacapavir https://pharmaphorum.com/news/gilead-tries-again-with-twice-yearly-hiv-drug-lenacapavir/
Celebrations for ASMD community as EU clears Sanofi’s Xenpozyme Sanofi has claimed approval in the EU for Xenpozyme as a treatment for acid sphingomyelinase deficiency (ASMD) – Share X Celebrations for ASMD community as EU clears Sanofi’s Xenpozyme https://pharmaphorum.com/news/celebrations-for-asmd-community-as-eu-clears-sanofis-xenpozyme/
Astellas pumps $90m into Sutro immuno-oncology alliance Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates Share X Astellas pumps $90m into Sutro immuno-oncology alliance https://pharmaphorum.com/news/astellas-pumps-90m-into-sutro-immuno-oncology-alliance/
Basilea preps key US filing for MRSA antibiotic ceftobiprole Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years Share X Basilea preps key US filing for MRSA antibiotic ceftobiprole https://pharmaphorum.com/news/basilea-preps-key-us-filing-for-mrsa-antibiotic-ceftobiprole/
Sanofi extends Health2Sync digital diabetes partnership to Japan Digital health company Health2Sync will work with Sanofi on digitising its range of insulin products in Japan, extending Share X Sanofi extends Health2Sync digital diabetes partnership to Japan https://pharmaphorum.com/news/sanofi-extends-health2sync-digital-diabetes-partnership-to-japan/
Study exposes lack of diversity in US cancer trials Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and Share X Study exposes lack of diversity in US cancer trials https://pharmaphorum.com/news/study-exposes-lack-of-diversity-in-us-cancer-trials/
Register for the Oligonucleotide Therapeutics and Delivery Conference Share X Register for the Oligonucleotide Therapeutics and Delivery Conference https://pharmaphorum.com/partner-content/register-for-the-oligonucleotide-therapeutics-and-delivery-conference/
Understanding the True Impact of the COVID-19 Pandemic on the Immunocompromised Share X Understanding the True Impact of the COVID-19 Pandemic on the Immunocompromised https://pharmaphorum.com/partner-content/understanding-the-true-impact-of-the-covid-19-pandemic-on-the-immunocompromised/
An introduction to case report forms Share X An introduction to case report forms https://pharmaphorum.com/partner-content/an-introduction-to-case-report-forms/
Data-Led Digital KOL Engagement Share X Data-Led Digital KOL Engagement https://pharmaphorum.com/partner-content/data-led-digital-kol-engagement/
AXON hires a Global Healthcare Insights and Strategy Lead Share X AXON hires a Global Healthcare Insights and Strategy Lead https://pharmaphorum.com/partner-content/axon-hires-a-global-healthcare-insights-and-strategy-lead/
Performance-io hires Lonneke Feskens to lead Europe Share X Performance-io hires Lonneke Feskens to lead Europe https://pharmaphorum.com/partner-content/performance-io-hires-lonneke-feskens-to-lead-europe/
